Skip to main content
. Author manuscript; available in PMC: 2010 Nov 8.
Published in final edited form as: Hear Res. 2009 Feb 6;252(1-2):61–70. doi: 10.1016/j.heares.2009.01.012

Table 2.

TGFβ signaling superfamily.

Type II Rreceptor Type 1 receptor Ligands R-SMAD
TGFβRII TGFβRI/ALK5 TGFβ1 SMAD1.5.8
AcvrL1/ALK1 TGFβ2 or
Acvr1/ALK2 TGFβ3 SMAD2,3
ACTIVIN-βA
Acvr2a Acvr1b/ALK4 ACTIVIN-βA,B,C,E SMAD2.3
Acvr1c/ALK7 BMP2 or
BMPRIB/ALK6 BMP6 SMAD1,5,8
BMPRIA/ALK3 BMP7
GDF5
GDF8
GDF9
GDF11
NODAL
Acvr2b Acvr1/ALK2 ACTIVIN-βA.B,C,E SMAD2,3
Acvr1b/ALK4 NODAL
Acvr1c/ALK7 BMP2
BMP6
BMP7
BMPRII Acvr1/ALK2 BMP2 SMAD1,5,8
BMPRIA/ALK3 BMP4
BMPRIB/ALKE BMP6
BMP7
GDF5
GDF6
GDF9
AMHR Acvr1/ALK2 MIS SMAD1,5,8
BMPRIA/ALK3
BMPRIB/ALKB

Type II Receptors: There are five Type II receptors; Transforming growth factor beta receptor (TGFbRII), Activin receptor A (Acvr2a), Activin receptor B (Acvr2b), Bone morphogenic protein receptor (BMPRII) and Anti-Mullerian hormone receptor (AMHR). Type I receptors are also called the Activin-like kinases (ALKs) and listed according to known dimerizations with type II receptors. Ligands that correspond to Type I and Type II receptor dimer binding are listed, however, not all of the TGFβ ligands are listed. Mullerian inhibitory substance (MlS), growth differentiation factor (GDF). SMAD signaling pathway associated with each receptor/ligand interaction is shown. Some receptor dimers can signal through either SMAD pathway depending on the activating ligand.